BPC-157 for Shoulder Pain:
What Research Shows
Preclinical studies show BPC-157 promotes rotator cuff tendon healing in animal models. Supraspinatus and infraspinatus recovery with total functional restoration. Here's the data breakdown.
🧪 Buy BPC-157 at Swiss Chems →2025 systematic review
rat rotator cuff model
trials to date
Shoulder Pain Affects Millions
Rotator cuff injuries are among the most common musculoskeletal complaints, and current treatments do not always restore full function.
What Is BPC-157?
Body Protection Compound-157 is a 15-amino-acid peptide derived from human gastric juice. Studied since the early 1990s for tissue healing across multiple organ systems — a 2025 systematic review identified 544 articles published from 1993 to 2024 and included 36 studies (35 preclinical, 1 clinical).
The Rotator Cuff Study: Data Breakdown
In 2014, researchers published a preclinical study on BPC-157's effects on surgically-induced rotator cuff tears in rats. The results showed remarkable recovery in treated animals.
Study design: Animal model (rat). Surgically-created rotator cuff tears involving supraspinatus and infraspinatus tendons. BPC-157 administered vs control. Outcomes measured: functional recovery, tendon healing, mobility, muscle strength.
Key Findings
"In animals treated with pentadecapeptide BPC 157 was observed total functional recovery similar to healthy animals, along with supraspinate and infraspinate tendon healing."
Sikiric et al. Effect of pentadecapeptide BPC 157 on rotator cuff tear injury in rat. FASEB Journal 2014
How BPC-157 Promotes Tendon Healing
A 2011 cell and tissue-explant study of rat Achilles tendon fibroblasts examined how BPC-157 may enhance tendon healing. It did not study the rotator cuff.
Chang CH, Tsai WC, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011 Mar;110(3):774-80.
PMID: 21030672 • View on PubMed →
Complete Mechanism Profile
A comprehensive 2025 systematic review (PMC12313605) synthesized 36 studies on BPC-157's musculoskeletal effects. Here's what the literature shows about how it works.
Why this matters for shoulders: Rotator cuff tendons have notoriously poor blood supply — the "critical zone" of the supraspinatus is especially vulnerable. BPC-157's ability to promote angiogenesis may address this fundamental healing limitation.
What the Human Knee Study Suggests
No human shoulder studies exist. The closest human data is a small retrospective knee pain study (PMID: 34324435): a phone survey of patient-recalled pain, with no imaging and no mechanism measured. Whether it applies to shoulder structures is untested.
Extrapolation caveat: The following data is from knee joint injections, not shoulders. Knees and shoulders share tissue types (tendons, ligaments, cartilage), but direct shoulder efficacy has not been tested in humans. Interpret cautiously.
| Factor | Knee Study Result | Potential Shoulder Application |
|---|---|---|
| Conditions Treated | Osteoarthritis, meniscus tears, ligament sprains | Rotator cuff tears, tendinitis, impingement (hypothetical) |
| Administration Route | Intra-articular injection | Glenohumeral joint or peri-tendon injection |
| Number of Injections | Not reported in the abstract | Unknown |
| Adverse Events | 0 of 12 (0%) | Unknown for shoulder administration |
| Relief Duration | Not reported in the abstract (most patients were surveyed 6-12 months after injection) | Untested |
| Evidence Level | Small retrospective phone survey (12 BPC-157-only patients), no placebo | No direct shoulder evidence |
Intra-articular BPC-157 injection for knee pain from osteoarthritis, meniscus tears, and ligament sprains.
PMID: 34324435 • View on PubMed →
BPC-157 vs Standard Shoulder Treatments
How does BPC-157's theoretical mechanism compare to established shoulder pain treatments? The BPC-157 column is based on preclinical data and the knee study methodology; the evidence base for the comparator treatments is not reviewed on this page.
| Factor | Cortisone | PRP | Physical Therapy | BPC-157 (Theoretical) |
|---|---|---|---|---|
| Mechanism | Suppresses inflammation | Growth factors from platelets | Strengthen surrounding muscles | Tissue repair + angiogenesis |
| Effect on Tissue | Not reviewed here | May promote healing | Not reviewed here | Promotes repair (preclinical) |
| FDA Status | FDA-approved | FDA-cleared devices | Standard of care | Not approved |
| Evidence Level | Not reviewed here | Not reviewed here | Not reviewed here | Preclinical only |
What We Know About BPC-157 Safety
The 2025 systematic review found no adverse effects in preclinical studies. However, clinical safety data remains extremely limited.
Critical limitation: Human clinical safety data for BPC-157 is very limited; a 2025 systematic review (PMC12313605), searching literature through June 3, 2024, found no clinical safety data. Products sold as "BPC-157" are unregulated — contamination, incorrect dosing, and impurities are possible. In 2023 the FDA placed BPC-157 in Category 2 of its bulk drug substances for compounding (substances that may present significant safety risks), citing immunogenicity, peptide impurities, and limited safety data. FDA's current list shows the nomination was later withdrawn by the nominators, and still lists the same potential safety risks for it.
Key Takeaways
- ✓ Animal study showed total functional recovery in rotator cuff tears
- ✓ BPC-157 promotes tendon fibroblast outgrowth, migration, and survival
- ✓ FAK-paxillin activation likely mediates tendon fibroblast migration (cell study)
- ✓ Enhances growth hormone receptor expression in tendons
- ✓ Small retrospective knee survey: 11 of 12 patients given BPC-157 alone reported significant improvement in knee pain
- ✗ No human clinical trials for shoulder-specific conditions
- ✗ Optimal dosing for shoulder/rotator cuff not established
- ✗ Best injection route for shoulder (intra-articular vs subcutaneous)
- ✗ Long-term safety in humans completely unknown
- ✗ Quality and purity of unregulated products variable
- ✗ Whether animal results translate to humans for shoulders
🛒 Recommended Products
Essential supplies for peptide reconstitution and injection protocols.
Affiliate links — support HighPeptides at no extra cost.
BPC-157 for Research
Sold for research use only. Products are unregulated, so quality and purity can vary.
Browse BPC-157 at Swiss Chems →Affiliate links — support HighPeptides at no extra cost.
Related HighPeptides Research
Frequently Asked Questions
In a preclinical animal study (Sikiric 2014), rats with surgically-induced rotator cuff tears showed "total functional recovery similar to healthy animals" when treated with BPC-157, along with reported supraspinatus and infraspinatus tendon healing. However, no human clinical trials have been conducted specifically for rotator cuff injuries — the animal results have not been validated in humans.
According to published research (PMID: 21030672), BPC-157 promotes tendon healing through multiple mechanisms: accelerating tendon fibroblast outgrowth from explants, increasing cell survival under oxidative stress, and promoting cell migration, which the authors conclude is likely mediated by activation of the FAK-paxillin pathway. Separately, a 2025 systematic review (PMC12313605) reports that the studies it included suggest BPC-157 enhances growth hormone receptor expression and pathways involved in angiogenesis (new blood vessel formation).
No. There are no published human clinical trials specifically for shoulder pain or rotator cuff injuries. The only relevant human data comes from a small retrospective knee study (PMID: 34324435): in a phone survey, 11 of 12 patients given BPC-157 alone reported significant improvement in knee pain for conditions including ligament and tendon injuries. The abstract does not report how long relief lasted, and whether these results apply to shoulder tendons has not been tested.
The knee study (PMID 34324435) used intra-articular injection only; no administration route has been tested for the shoulder in humans. The rotator cuff animal study used intraperitoneal injection. Route selection should be guided by a qualified medical professional. Self-administration is not recommended.
No. BPC-157 is not FDA-approved for any medical condition. In 2023, the FDA placed it in Category 2 of its bulk drug substances for compounding (substances that may present significant safety risks), citing immunogenicity, peptide impurities, and limited safety data. FDA's current list shows BPC-157 among substances whose nominations were later withdrawn by the nominators, and still lists the same potential safety risks for it. It remains a research peptide with no approved clinical indications.
⚕️ Medical Disclaimer
This page is for educational and informational purposes only. It is not medical advice. BPC-157 is not FDA-approved for any medical condition. The studies cited are preliminary — animal models and small human studies without placebo controls. No human clinical trials exist for shoulder-specific conditions. Always consult a qualified healthcare professional before making decisions about any peptide, supplement, or treatment protocol. Do not use this information to self-diagnose or self-treat any condition.
47-page guide: protocols, dosing, sourcing — everything in one place.
Get the guide — $19 (normally $29) → New to peptides? Start with the $19 Buyer’s Playbook → All ebooks & guides →Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars — metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.